{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:27:35Z","timestamp":1785493655511,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007439","name":"Jan Wallanders och Tom Hedelius Stiftelse samt Tore Browaldhs Stiftelse","doi-asserted-by":"publisher","award":["P21-0018"],"award-info":[{"award-number":["P21-0018"]}],"id":[{"id":"10.13039\/100007439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.esmoop.2022.100569","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T05:57:31Z","timestamp":1661666251000},"page":"100569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0940-9166","authenticated-orcid":false,"given":"G.","family":"Chauca Strand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1189-9950","authenticated-orcid":false,"given":"C.","family":"Bonander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7143-8793","authenticated-orcid":false,"given":"N.","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-7478","authenticated-orcid":false,"given":"M.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100569_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","article-title":"The cost of cancer in Europe 2018","volume":"129","author":"Hofmarcher","year":"2020","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100569_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","article-title":"Economic burden of cancer across the European Union: a population-based cost analysis","volume":"14","author":"Luengo-Fernandez","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100569_bib3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bjc.2015.56","article-title":"Development and economic trends in cancer therapeutic drugs: a 5-year update 2010\u20132014","volume":"112","author":"Savage","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100569_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1078155210389218","article-title":"Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009","volume":"18","author":"Savage","year":"2012","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.esmoop.2022.100569_bib5","author":"IQVIA Global"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100569_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the market for anticancer drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J\u00a0Econ Perspect"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100569_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100569_bib8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(11)70141-3","article-title":"Delivering affordable cancer care in high-income countries: a Lancet Oncology Commission","volume":"12","author":"Sullivan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100569_bib9","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S1470-2045(13)70578-3","article-title":"Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care","volume":"15","author":"Kelly","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100569_bib10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41571-022-00636-y","article-title":"An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?","volume":"19","author":"Cherny","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100569_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2020.01.020","article-title":"Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015","volume":"129","author":"Gr\u00f6ssmann","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100569_bib12","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100569_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and drug administration approvals","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.esmoop.2022.100569_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.12.026","article-title":"Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015","volume":"110","author":"Gr\u00f6ssmann","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100569_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.esmoop.2022.100569_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A\u00a0systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100569_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100569_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-020-05615-4","article-title":"Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer","volume":"181","author":"Hirai","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100569_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-06910-5","article-title":"Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials","volume":"20","author":"Nie","year":"2020","journal-title":"BMC Cancer"},{"issue":"33","key":"10.1016\/j.esmoop.2022.100569_bib20","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","article-title":"Progression-free survival is a surrogate for survival in advanced colorectal cancer","volume":"25","author":"Buyse","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100569_bib21","doi-asserted-by":"crossref","first-page":"j4528","DOI":"10.1136\/bmj.j4528","article-title":"Do cancer drugs improve survival or quality of life?","volume":"359","author":"Prasad","year":"2017","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100569_bib22","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100569_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/annonc\/mdw132","article-title":"Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer","volume":"27","author":"Michiels","year":"2016","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2022.100569_bib24","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1200\/JCO.2005.08.156","volume":"23","author":"Collette","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100569_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jval.2013.10.008","article-title":"A\u00a0synthesis of drug reimbursement decision-making processes in Organisation for Economic Co-operation and Development Countries","volume":"17","author":"Barnieh","year":"2014","journal-title":"Value in Health"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100569_bib26","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40273-015-0307-6","article-title":"Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness","volume":"33","author":"Svensson","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100569_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jval.2014.12.008","article-title":"Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006\u20132013","volume":"18","author":"Charokopou","year":"2015","journal-title":"Value in Health"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100569_bib28","first-page":"352","article-title":"\u201cYes\u201d","volume":"77","author":"Dakin","year":"2006","journal-title":"\u201cNo\u201d or \u201cYes, but\u201d? Multinomial modelling of NICE decision-making. Health Policy"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100569_bib29","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/hec.3086","article-title":"The influence of cost-effectiveness and other factors on NICE decisions","volume":"24","author":"Dakin","year":"2015","journal-title":"Health Econ"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100569_bib30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jval.2019.10.010","article-title":"Association between the use of surrogate measures in pivotal trials and health technology assessment decisions: a retrospective analysis of NICE and CADTH reviews of cancer drugs","volume":"23","author":"Pinto","year":"2020","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100569_bib31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40273-018-0610-0","article-title":"The relative importance of clinical, economic, patient values and feasibility criteria in cancer drug reimbursement in Canada: a revealed preferences analysis of recommendations of the Pan-Canadian Oncology Drug Review 2011\u20132017","volume":"36","author":"Skedgel","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100569_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13023-019-1104-7","article-title":"Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada","volume":"14","author":"Nagase","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100569_bib33","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bcp.13531","article-title":"Balancing early access with uncertainties in evidence for drugs authorized by prospective case series-systematic review of reimbursement decisions","volume":"84","author":"Wallerstedt","year":"2018","journal-title":"Br J Clin Pharm"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100569_bib34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/imj.13350","article-title":"Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia","volume":"47","author":"Karikios","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.esmoop.2022.100569_bib35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jclinepi.2017.07.002","article-title":"Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview","volume":"90","author":"Woolacott","year":"2017","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100569_bib36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jval.2015.02.011","article-title":"Assessment of the quality of the clinical evidence in submissions to the Australian pharmaceutical benefits advisory committee: fit for purpose?","volume":"18","author":"Wonder","year":"2015","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100569_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40273-012-0022-5","article-title":"The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada","volume":"31","author":"Yong","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100569_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100166","article-title":"Twelve years of European cancer drug approval\u2014a systematic investigation of the \u2018magnitude of clinical benefit","volume":"6","author":"Gr\u00f6ssmann","year":"2021","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100569_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamainternmed.2020.8588","article-title":"Evaluation of the clinical benefit of cancer drugs submitted for reimbursement recommendation decisions in Canada","volume":"181","author":"Meyers","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.esmoop.2022.100569_bib40","unstructured":"Lag (2020:160) om l\u00e4kemedelsf\u00f6rm\u00e5ner m.m. \u00a715. Socialdepartamentet. 2002."},{"key":"10.1016\/j.esmoop.2022.100569_bib41","author":"TLV Handbok"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100569_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-01901-6","article-title":"Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases","volume":"16","author":"Miller","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.esmoop.2022.100569_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.socscimed.2014.12.007","article-title":"Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?","volume":"131","author":"Davis","year":"2015","journal-title":"Soc Sci Med"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100569_bib44","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.2009.25.4672","article-title":"End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences","volume":"28","author":"Mack","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.esmoop.2022.100569_bib45","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100569_bib46","article-title":"Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence","volume":"2012","author":"Rossari","year":"2012","journal-title":"J\u00a0Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100569_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40290-014-0063-5","article-title":"The influence of cost-effectiveness evaluations on reimbursement in Australia: a retrospective study of decisions made by the Pharmaceutical Benefits Advisory Committee","volume":"28","author":"Ngo","year":"2014","journal-title":"Pharmaceutical Med"},{"key":"10.1016\/j.esmoop.2022.100569_bib48","first-page":"DX44","article-title":"TLV:s betalningsvilja f\u00f6r nya l\u00e4kemedel har analyserats: Kostnadseffektivitet och sjukdomens sv\u00e5righetsgrad avg\u00f6rande f\u00f6r subvention-Cancerl\u00e4kemedel f\u00e5r kosta mer","volume":"113","author":"Svensson","year":"2016","journal-title":"L\u00e4kartidningen"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100569_bib49","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100569_bib50","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","article-title":"Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration","volume":"180","author":"Hilal","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100569_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-015-1023-4","article-title":"A\u00a0literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.esmoop.2022.100569_bib52","author":"Troiein"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:33Z","timestamp":1761856113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922001983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2059702922001983"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100569","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100569"}}